Reyes LA, Lemus-Carmona E, Orozco BEA

Language: Spanish
References: 12
Page: 238-246
PDF size: 257.28 Kb.

ABSTRACT

Chronic obstructive pulmonary disease is a progressive disease with irreversible effects on lung function. In Mexico it is an important disease for its morbidity and mortality, however, remains under-diagnosed and under-recognized as a public health problem. They require cost-effective drugs with long lasting effect that will raise the quality of life of patients. There have been describe ultra-LABAs (long-term beta agonists) as an excellent treatment option. Indacaterol is a novel molecule of this newly created therapeutic class. This molecule is a fast-acting beta2-agonist with prolonged effect, which provides an onset of action within 5 minutes, but with a sustained bronchodilator effect, which is maintained for 24 hours. The objective of this evaluation is to establish the cost-effectiveness profile of indacaterol compared with tiotropium and salmeterol in patients with moderate to severe chronic obstructive pulmonary disease, using economic modeling techniques from the perspective of the health system in Mexico. In this pharmacoeconomic analysis conducted we found that indacaterol is a dominant alternative, for having been less cost (14.3 and 8.8%, respectively) and more effective (reported as 0.2 and 0.6% in QUALY efficacy, respectively) than their comparators, tiotropium and salmeterol.

REFERENCES

1. Consenso Mexicano de EPOC. Panorama epidemiológico e impacto económico actual. Panorama epidemiológico e impacto económico actual. Neumología y Cirugía de Tórax. 2007; 66 (S2): S13-S16.

2. Donohue JF, Fogarty C, Lötvall J, Mahler DA, Worth H, Yorgancioglu A et al. Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium. Am J Respir Crit Care Med. 2010; 182 (2): 155-162.

3. Kornmann O, Dahl R, Centanni S. Once-daily indacaterol versus twice-daily salmeterol for COPD: a placebo controlled comparison. Eur Respir J. 2010; 37 (2): 273-279.

4. Voglemeier C, Ramos-Barbon D, Jack D. Indacaterol provides 24-hour bronchodilation in COPD: a placebo-controlled blinded comparison with tiotropium. Respir Res. 2010; 11 (135).

5. Laforce C, Aumann J, de Teresa PL, Iqbal A, Young D, Owen R et al. Sustained 24-hour efficacy of once daily indacaterol (300 mug) in patients with chronic obstructive pulmonary disease: a randomized, crossover study. Pulm Pharmacol Ther. 2010; 24 (1): 162-168.

6. Magnussen H, Verkindre C, Jack D, Jadayel D, Henley M, Woessner R et al. Indacaterol once-daily is equally effective dosed in the evening or morning in COPD. Respir Med. 2010; 104 (12): 1869-1876.

7. Feldman G, Siler T, Prasad N, Jack D, Piggott S, Owen R et al. Efficacy and safety of indacaterol 150 ug once-daily in COPD: a double-blind, randomized, 12-week study. BMC Pulm Med. 2010; 10: 11.

8. Fogarty C et al. Sustained 24-h bronchodilation with QAB149 Once-Daily in COPD: A 26-week efficacy and safety study. Poster presented at American Thoracic Society (ATS) 2009 international conference, May 2009.

9. Chung KF, Kornmann O, Jack D, Owen R, Kramer B, Higgins M. Safety and tolerability of indacaterol over 52 weeks of treatment in COPD. Am J Respir Crit Care Med. 179; 2009: A45-46.

10. Rossi A, Centanni S, Cerveri I, Gulotta C, Foresi A, Cazzola M et al. Acute effects of indacaterol on lung hyperinflation in moderate COPD: A comparison with tiotropium. Respir Med. 2011 [Epub ahead of print].

11. Price D, Gray A, Gale R, Asukai Y, Mungapen L, Lloyd A, Peters L, Neidhardt K, Gantner T. Cost-utility analysis of indacaterol in Germany: A once-daily maintenance bronchodilator for patients with COPD. Respiratory Medicine. 2011; 105 (11): 1635-1647.

12. Mihălţan F. indacaterol-a new hope for maximizing bronchodilation? Pneumologia. 2011; 60 (1): 21-25.